老年急性冠脉综合征病人血清α1抗胰糜蛋白酶水平及其临床意义

doi:10.3969/j.issn.1003-9198.2022.03.008

摘要/Abstract

摘要： 目的探讨老年急性冠脉综合征(ACS)病人血清α1抗胰糜蛋白酶(AACT)水平及其临床意义。方法采用ELISA法分别检测ACS病人[包括急性心肌梗死(AMI)和不稳定型心绞痛(UAP)]、稳定型心绞痛病人(SAP组)和对照组(C组)血清中AACT、IL-6水平,通过ROC曲线分析AACT水平对ACS的诊断价值。采用Western Blot法检测人重组AACT蛋白干预人冠状动脉内皮细胞(HCAEC)后AACT及IL-6的表达。结果 ACS病人血清中AACT及IL-6水平均明显高于SAP组和C组(P<0.01)。ROC曲线分析提示,AACT水平对ACS具有良好的诊断价值(曲线下面积为0.951),最佳诊断界值为12.40 ng/mL,灵敏度为84.26%,特异度为84.29%(P<0.01)。人重组AACT蛋白(100 ng/mL)干预HCAEC后,内皮细胞AACT及IL-6表达显著上调(P<0.01)。结论 AACT促进内皮细胞炎症因子的表达,其血清水平可作为ACS的诊断标志物。

关键词: α1抗胰糜蛋白酶, 老年人, 急性冠脉综合征, 内皮炎症因子

Abstract: Objective To explore the clinical significance of serum α1-antichymotrypsin (AACT)levels in the elderly patients with acute coronary syndrome (ACS). Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of AACT and interleukin-6 (IL-6) in the elderly patients with ACS (including acute myocardial infarction and unstable angina pectoris),stable angina pectoris (SAP) and controls. Receiver operating characteristic (ROC) curve was constructed to analyze the diagnostic value of AACT for ACS. Western Blot was applied to determine the expression of AACT and IL-6 in human coronary artery endothelial cells (HCAEC) treated with or without recombinant human AACT protein. Results The serum levels of AACT and IL-6 in the ACS patients were significantly higher than those in SAP group and control group (P<0.01). ROC analysis revealed that the optimal cut-off value of AACT level for the diagnosis of ACS was 12.40 ng/mL, with a sensitivity of 84.26% and a specificity of 84.29%, and the area under the curve was 0.951(P<0.01). The expression of AACT and IL-6 was significantly up-regulated in HCAEC treated with human recombinant AACT protein (100 ng/mL) (P<0.01). Conclusions AACT promotes the endothlial inflammation, and the serum AACT level can be used as a diagnostic marker for ACS.

Key words: α1-antichymotrypsin, aged, acute coronary syndrome, endothlial inflammation factor

中图分类号:

R 541.4

左广锋, 谢浩, 任晓敏, 郑亚国, 金国珍, 林松. 老年急性冠脉综合征病人血清α1抗胰糜蛋白酶水平及其临床意义[J]. 实用老年医学, 2022, 36(3): 244-248.

ZUO Guang-feng, XIE Hao, REN Xiao-min, ZHENG Ya-guo, JIN Guo-zhen, LIN Song. Clinical significance of serum α1-antichymotrypsin level in elderly patients with acute coronary syndrome[J]. Practical Geriatrics, 2022, 36(3): 244-248.

参考文献

[1] WANG L, JIN Y. Noncoding RNAs as biomarkers for acute coronary syndrome[J]. Biomed Res Int, 2020, 2020:3298696.
[2] 黄钰晨, 胡美迪.急性冠脉综合征常用药物在老年患者中的应用进展[J]. 江西医药,2020,55(8):1140-1142.
[3] WU S, SUN H, SUN B. MicroRNA-145 is involved in endothelial cell dysfunction and acts as a promising biomarker of acute coronary syndrome[J]. Eur J Med Res,2020, 25(1):2.
[4] SMYKIEWICZ P, SEGIET A, KEAG M, et al. Proinflammatory cytokines and ageing of the cardiovascular-renal system[J]. Mech Ageing Dev, 2018, 175:35-45.
[5] SOYSAL P, ARIK F, SMITH L, et al. Inflammation, frailty and cardiovascular disease[J]. Adv Exp Med Biol, 2020,1216:55-64.
[6] SANCHEZ-NAVARRO A, GONZALEZ-SORIA I, CALDINO-BOHN R, et al. An integrative view of serpins in health and disease: the contribution of serpinA3[J]. Am J Physiol Cell Physiol, 2021, 320(1):C106-C118.
[7] TAKAHASHI E, UNOKI-KUBOTA H, SHIMIZU Y, et al. Proteomic analysis of serum biomarkers for prediabetes using the Long-Evans Agouti rat, a spontaneous animal model of type 2 diabetes mellitus[J]. J Diabetes Investig, 2017, 8(5):661-671.
[8] ZHANG Y, TIAN J, QU C, et al. Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells[J]. Breast Cancer, 2021, 28(4):859-873.
[9] MEIJERS W C, MAGLIONE M, BAKKER S J L, et al. Heart failure stimulates tumor growth by circulating factors[J]. Circulation,2018,138(7):678-691.
[10] ZHAO L, ZHENG M, GUO Z, et al. Circulating serpina3 levels predict the major adverse cardiac events in patients with myocardial infarction[J]. Int J Cardiol, 2020, 300:34-38.
[11] 中国医师协会急诊医师分会,国家卫健委能力建设与继续教育中心急诊学专家委员会,中国医疗保健国际交流促进会急诊急救分会.急性冠脉综合征急诊快速诊治指南 (2019)[J]. 中华急诊医学杂志,2019,28(4):421-428.
[12] Task Force Members. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology[J]. Eur Heart J, 2013, 34(38):2949-3003.
[13] LIU H, LI G, ZHAO W, et al. Inhibition of MiR-92a may protect endothelial cells after acute myocardial infarction in rats: role of KLF2/4[J]. Med Sci Monit, 2016, 22:2451-2462.
[14] JEONG H S, HONG S J, CHO S A, et al. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulating endothelial progenitor cells in diabetic patients with non-ST segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial[J]. JACC Cardiovasc Interv, 2017,10(16):1646-1658.
[15] FERRUCCI L, FABBRI E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty[J]. Nat Rev Cardiol, 2018, 15(9):505-522.
[16] TURNIER J L, BRUNNER H I, BENNETT M, et al. Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity[J]. Rheumatology: Oxford, 2019, 58(2):321-330.
[17] WAGSATER D, JOHANSSON D, FONTAINE V, et al. Serine protease inhibitor A3 in atherosclerosis and aneurysm disease[J]. Int J Mol Med, 2012, 30(2):288-294.
[18] CHEOW E S H, CHENG W C, YAP T, et al. Myocardial injury is distinguished from stable angina by a set of candidate plasma biomarkers identified using iTRAQ/MRM-based approach[J]. J Proteome Res, 2018,17(1):499-515.
[19] LIBBY P, PASTERKAMP G, CREA F, et al. Reassessing the mechanisms of acute coronary syndromes[J]. Circ Res, 2019,124(1):150-160.
[20] MOUROUZIS K, OIKONOMOU E, SIASOS G, et al. Pro-inflammatory cytokines in acute coronary syndromes[J]. Curr Pharm Des,2020,26(36):4624-4647.
[21] GAGER G M, BIESINGER B, HOFER F, et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome[J]. Vascul Pharmacol,2020,135:106806.
[22] LI H, CEN K, SUN W, et al. Predictive value of blood interleukin-6 level in patients with acute coronary syndrome: a meta-analysis[J]. Immunol Invest, 2020, 50(8):964-976.